Objective To observe the efficacy and safety of Ginkgo biloba extract combined with Nimodipine on patients with acute cerebral infarction.Methods 106 cases of acute cerebral infarction were randomly divided into two groups(control group and treatment group),the control group was given Nimodipine on the basis of regular treatment,and the treatment group was given Ginkgo biloba extract combined with Nimodipine on the basis of regular treatment.Results The total effective rate of treatment group was higher than that of the control group (x2 =3.62,P ＜0.05),improvement of neurological deficit was better than that of the control group (t =2.57,5.32,all P ＜ 0.05),Plasma TC and TG levels were significantly lower than that of the control group(t =4.23,6.43,all P ＜ 0.05).During treatment,patients had no serious adverse reactions.Conclusion Ginkgo biloba extract and Nimodipine have synergistic effects,the two combined treatment of acute cerebral infarction have significantly effects,which is safe and reliable.

Objective: To study the anti-complementary anthraquinones from Polygonum cuspidatum and their action targets. Methods: The anti-complementary activity-directed isolation was carried out with the hemolysis test as guide. All isolates were evaluated for their in vitro anti-complementary activities. The action targets of the main bioactive constituents were also examined using complement-depleted sera. Results: Ten anthraquinones and three other compounds were isolated from the EtOAc fraction of P. cuspidatum extract, including physcion (1), chrysophanol (2), questin (3), emodin-8-O-β-D-glucoside (4), emodin (5), rhein (6), fallacinol (7), citreorosein (8), xanthorin (9), isorhodoptilometrin (10), 2, 5-dimethyl-7-hydroxychromone (11), 7-hydroxy-4-methoxy-5-methylcoumarin (12), and 5, 7-dihydroxy-1-isobenzofuranone (13). Compounds 9 and 10 were isolated from the the plants of Polygonaceae for the first time, and compound 9 was the alizarin-type anthraquinone first obtained from P. cuspidatum. Compounds 3-9 showed the anti-complementary activity in different degrees, and compound 7 exhibited the most significant activity against the classical and alternative pathway [CH50 = (6 ± 2) μg/mL, AP50 = (50 ± 5) μg/mL]. The study on the preliminary mechanism revealed that compound 4 interacted with C1q, C2, and C9 in complement activation cascade, while compound 7 acted on C1q, C2, C4, and C9. Conclusion: The anthraquinones are main anti-complementary constituents in P. cuspidatum; and fallacinol (7) is a potential complement inhibitor with strong activity and definite targets, which should be further studied in future.

Objective To observe the efficacy and prognosis of aconite-cake-partitioned moxibustion plus acupuncture in treating peptic ulcer.Method Thirty-four patients in the treatment group were intervened by aconite-cake-partitioned moxibustion plus acupuncture, while thirty-three patients in the control group were by Omeprazole Enteric-coated Capsules. The clinical efficacy, the effect on ulcer under gastroscope and Hp, and the therapeutic efficacy 12 months after the intervention were evaluated.Result The total effective rate was 91.2% in the treatment group versus 72.7% in the control group, and the difference was statistically significant (P<0.05). For ulcer by gastroscopy, the total effective rate was 85.3% in the treatment group versus 69.7% in the control group, and the difference was statistically significant (P<0.05). After intervention, the Hp level didn’t show significant change (P>0.05). The relapse rate of the control group was higher than that of the treatment group 12 months after the intervention.Conclusion Aconite-cake-partitioned moxibustion plus acupuncture can produce a higher efficacy than Western medication in treating peptic ulcer.

Obesity has been widely accepted as a metabolic disease and its occurrence is closely related to the genetics, environment, and inflammation. Up to now, body mass index is still regarded as the standard diagnostic criterion for obesity. It has not been revised for decades and could not meet the needs of clinical diagnosis and demands for specific treatment at present. In 2013, the concept of metabolic obesity was introduced at the American Diabetes Association ( ADA) annual conference, and it was further proposed that obesity should be classified according to the metabolic status and its related complications at the 2014 American Association of Clinical Endocrinologists ( AACE) annual conference. This means that scientists and clinicians have realized that the etiology of obesity may vary with different outcomes, the treatment should be focused on the metabolic regulation, not merely on weight loss. With years of clinical practice and research in obesity, we have observed and treated numerous obese patients, and we have found that obesity has a lot of phenotypes and clinical features which are related to the metabolic status. Based on our clinical findings, combined with the experience of Chinese traditional medicine, we now propose a new clinical classification and diagnosis of obesity based on individuals′ metabolic status, which, we believe, can facilitate clinicians′practice. Based on the metabolic status and skin features of obese patients, obesity is divided into metabolic healthy obesity (‘white obesity’) and metabolic unhealthy obesity. Then, the latter is further divided into three groups including high metabolic obesity (‘red obesity’ ) , low metabolic obesity (‘yellow obesity’ ) , and severe metabolic disorder with inflammation obesity (‘black obesity’ ) . If we also consider to add normal weight metabolic obesity to this classification, there should be five types of obesity to be classified as presented. We wish this proposed classification of obesity can play a valuable role in enabling clinicians to have a better understanding of obesity in relation to its metabolism, and to develop individualized treatment according to the metabolic status of the patient. As a result, we may finally achieve the desired outcomes through making appropriate diagnosis and treatments.

Bone is the most common site for metastasis from prostate cancer, and bone metastases also is one of the main causes for the death of the patients with prostate cancer. Since the patients with bone metastases from prostate cancer still have relatively long survival periods after treatmemt, how to properly choose the treatment option for the metastatic patients is imperative in terms of improvements in both quality of life and life expectation. This paper summary pathophysiology, risk evaluation clinical assessment and the current status of the treatment options of prostate cancer with bone metastases, it also lays out the background for the individualized treatment plan that still needs to be further investigated.

Objective To observe the therapeutic efficacy of acupuncture plus moxibustion in treating chemoradiotherapy-induced leukopenia in patients with malignant tumors.Method A total of 120 patients with malignant tumors who presentedleukopenia during receiving chemoradiotherapy were randomized into two groups. Sixty cases in the treatment group were intervened by acupuncture plus moxibustion; sixty cases in the control group were intervened by oral administration of Batilol tablets and Leucogen tablets.The peripheral white blood cell (WBC) count in the two groups was detected on treatment day 3, 7, 14, 21, and 28.The clinical efficacies of the two groups were compared.ResultThe WBC started toincreaseafter 1-week treatment in thetreatment group (P<0.05) and the increase was statistically significant after 2-week treatment (P<0.01); in the control group, the WBC started to increase after 2-week treatment (P<0.05)and the increase was statistically significant after 3-week treatment (P<0.01); the effect of increasing WBC was more significant in the treatment group compared to the control group (P<0.05,P<0.01).The total effective rate was 90.0% in the treatment group versus 53.3% in the control group, and the between-group difference was statistically significant (P<0.01).Conclusion Acupuncture plus moxibustion can produce a significant efficacy in treating leukopenia induced by chemoradiotherapy.

OBJECTIVE:To provide the reference for the Chinese government to establish medication policy in paediatrics.METHODS:The paediatric medication strategy set up by British Drug and Health Product Administration Bureau was introduced,and the current situation and problems in paediatric medication were analyzed.RESULTS & CONCLUSION:China should learn from British experience,and establish our own medication strategy in paediatrics as soon as possible.

Hilar cholangiocarcinoma (HCCA) or Klatskin tumor is a scirrhous adenocarcinoma that arises from the conjunction of bile duct and hepatic ducts.Hepatic magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatography (MRCP) are important methods for the diagnosis of HCCA.In this article,the clinical data of 42 patients in the Changhai Hospital and 18 patients in the Eastern Hepatobiliary Surgery Hospital who received MRI and MRCP examination from October 2010 to October 2012 were retrospectively analyzed.According to the pathological features,HCCA could be divided into mass-forming type,infiltrating type and intraductal type.Based on the results of imaging examination and intra-and postoperative pathological examination,Bismuth-Corlette types were decided pre-and postoperatively.The coincidence rate of pre-and postoperative Bismuth-Corlette types was 89.7％ (35/39).Infiltration of liver parenchyma was both detected pre-and postoperatively in 19 patients (16 patients were detected by MRI preoperatively),and the sensitivity of MRI was 84.2％ ; vascular invasion was both detected pre-and postoperatively in 10 patients (12 patients were detected by MRI preoperatively),and the sensitivity of MRI was 83.3％ ; hilar and retroperitoneal lymph node metastasis was both detected pre-and postoperatively in 6 patients (4 patients were detected by MRI preoperatively),and the sensitivity of MRI was 66.7％.Combined application of different sequences and techniques of MRI is helpful in the diagnosis,staging and treatment of HCCA.

To observe the efficacy of fumigation with Fumigant I formula, a compound traditional Chinese herbal medicine, in treating adjuvant arthritis (AA) in rats and to explore its anti-inflammation mechanism.

Objective To study the mechanism of toxicity of hexane. Methods SD rats inhaled 15 g/ma n-hexane statically for 8 hours. Results The levels of GSH in whole blood of rats declined significantly (t-test,P＜0. 01). The levels of MDA in serum of rats revealed increasing trend but without statistical significance (t-test,P＞0. 05). The activities of SOD and GSH-Px in liver of rats decreased significantly (t-test,P＜0.01). Conclusion n-Hexane could induce or enhance the reaction of oxygen free radical in organism,and result in damages of lipid peroxidation,which might be one of the mechanisms of the toxicity of alkane.